Cardiac Safety of Osimertinib: A Review of Data von Ewer, Michael S, Tekumalla, Sri Harsha, Walding, Andrew, Atuah, Kwame N

Volltext

Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact? von Ewer, Michael S, Swain, Sandra M

Volltext

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity von Ewer, Michael S, Lippman, Scott M

Volltext

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzu... von ROMOND, Edward H, JEONG, Jong-Hyeon, FLYNN, Patrick J, ZAPAS, John L, POLIKOFF, Jonathan, GROSS, Howard M, BIGGS, David D, ATKINS, James N, TAN-CHIU, Elizabeth, PING ZHENG, YOTHERS, Greg, MAMOUNAS, Eleftherios P, RASTOGI, Priya, WOLMARK, Norman, SWAIN, Sandra M, GEYER, Charles E, EWER, Michael S, RATHI, Vikas, FEHRENBACHER, Louis, BRUFSKY, Adam, AZAR, Catherine A

Volltext

Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? von Ewer, Michael S, Lenihan, Daniel J

Volltext

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvan... von Buzdar, Aman U, Prof, Suman, Vera J, Prof, Meric-Bernstam, Funda, Prof, Leitch, A Marilyn, Prof, Ellis, Matthew J, Prof, Boughey, Judy C, MD, Unzeitig, Gary, MD, Royce, Melanie, Prof, McCall, Linda M, MS, Ewer, Michael S, Prof, Hunt, Kelly K, Prof

Volltext

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials von Perez, Edith A., MD, Koehler, Maria, MD, PhD, Byrne, Julie, PhD, Preston, Alaknanda J., PhD, Rappold, Erica, BSN, Ewer, Michael S., MD, JD

Volltext

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology von Eschenhagen, Thomas, Force, Thomas, Ewer, Michael S., de Keulenaer, Gilles W., Suter, Thomas M., Anker, Stefan D., Avkiran, Metin, de Azambuja, Evandro, Balligand, Jean-Luc, Brutsaert, Dirk L., Condorelli, Gianluigi, Hansen, Arne, Heymans, Stephane, Hill, Joseph A., Hirsch, Emilio, Hilfiker-Kleiner, Denise, Janssens, Stefan, de Jong, Steven, Neubauer, Gitte, Pieske, Burkert, Ponikowski, Piotr, Pirmohamed, Munir, Rauchhaus, Mathias, Sawyer, Douglas, Sugden, Peter H., Wojta, Johann, Zannad, Faiez, Shah, Ajay M.

Volltext

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials von Perez, Edith A., Koehler, Maria, Byrne, Julie, Preston, Alaknanda J., Rappold, Erica, Ewer, Michael S.

Volltext

Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment von EWER, Michael S, VOOLETICH, Mary T, DURAND, Jean-Bernard, WOODS, Myrshia L, DAVIS, Joseph R, VALERO, Vicente, LENIHAN, Daniel J

Volltext

False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters von Ewer, Michael S., Herson, Jay

Volltext

Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports von Ewer, Michael S, Herson, Jay

Volltext

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human... von BUZDAR, Aman U, IBRAHIM, Nuhad K, CRISTOFANILLI, Massimo, FRYE, Debra K, SMITH, Terry L, HUNT, Kelly K, SINGLETARY, Sonja E, SAHIN, Aysegul A, EWER, Michael S, BUCHHOLZ, Thomas A, BERRY, Donald, FORTOBAGYI, Gabriel N, FRANCIS, Deborah, BOOSER, Daniel J, THOMAS, Eva S, THERIAULT, Richard L, PUSZTAI, Lajos, GREEN, Marjorie C, ARUN, Banu K, GIORDANO, Sharan H

Volltext

Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2... von BUZDAR, Aman U, VALERO, Vicente, SAHIN, Aysegul A, ESTEVA, Francisco, SYMMANS, William F, EWER, Michael S, BUCHHOLZ, Thomas A, HORTOBAGYI, Gabriel N, IBRAHIM, Nuhad K, FRANCIS, Deborah, BROGLIO, Kristine R, THERIAULT, Richard L, PUSZTAI, Lajos, GREEN, Marjorie C, SINGLETARY, Sonja E, HUNT, Kelly K

Volltext

Editorial: Case reports in cardio-oncology: 2022 von Ewer, Michael S, Yusuf, Syed Wamique, Asmis, Reto, Abe, Jun-Ichi

Volltext

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC von Ewer, Michael S., Ewer, Steven M.

Volltext

Reply to K. Anand et al and K. Kunimasa von Ewer, Michael S

Volltext

Cancer drugs and the heart: importance and management von Suter, Thomas M, Ewer, Michael S

Volltext

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up von Piccart, Martine, Procter, Marion, Fumagalli, Debora, de Azambuja, Evandro, Clark, Emma, Ewer, Michael S, Restuccia, Eleonora, Jerusalem, Guy, Dent, Susan, Reaby, Linda, Bonnefoi, Hervé, Krop, Ian, Liu, Tsang-Wu, Pieńkowski, Tadeusz, Toi, Masakazu, Wilcken, Nicholas, Andersson, Michael, Im, Young-Hyuck, Tseng, Ling Ming, Lueck, Hans-Joachim, Colleoni, Marco, Monturus, Estefania, Sicoe, Mihaela, Guillaume, Sébastien, Bines, José, Gelber, Richard D, Viale, Giuseppe, Thomssen, Christoph

Volltext

Cardiac Monitoring Guidelines in Clinical Trials and Post-Approval Surveillance for Patients Exposed to Anticancer Treatments: Do the Data Support the Recommendations? von Ewer, Michael S., Palaskas, Nicolas L., Herson, Jay

Volltext